Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d146117c45d28df3e764135479e51e58 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16634 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6081 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-087 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-25 |
filingDate |
1997-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d90132c08caad4b1b92ac52af93044bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6970afa2a240facd050f7c76aca7fcd5 |
publicationDate |
1997-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2283633-A1 |
titleOfInvention |
Peptide vaccine to prevent development of several herpes virus infections and/or atherosclerotic plaque |
abstract |
A vaccine is disclosed for the prophylaxis against pathogenic development of atherosclerotic plaque in a mammalian subject susceptible thereto which comprises: 10 to 30 % by weight of the compound of SEQ ID 2; 10 to 30 % by weight of the compound of SEQ ID 4; 10 to 30 % by weight of the compound of SEQ ID 6; 10 to 30 % by weight of the compound of SEQ ID 8 in combination with a pharmaceutically acceptable innert carrier. |
priorityDate |
1996-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |